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Hepatitis C virus (HCV) is an important human pathogen that causes acute and chronic hepatitis, cirrhosis and
hepatocellular carcinoma worldwide. This positive stranded RNA virus is extremely efficient in establishing persistent
infection by escaping immune detection or hindering the host immune responses. Recent studies have discovered
two important signaling pathways that activate the host innate immunity against viral infection. One of these
pathways utilizes members of Toll-like receptor (TLR) family and the other uses the RNA helicase retinoic acid
inducible gene I (RIG-I) as the receptors for intracellular viral double stranded RNA (dsRNA), and activation of
transcription factors. In this review article, we summarize the interaction of HCV proteins with various host
receptors/sensors through one of these two pathways or both, and how they exploit these interactions to escape
from host defense mechanisms. For this purpose, we searched data from Pubmed and Google Scholar. We found
that three HCV proteins; Core (C), non structural 3/4 A (NS3/4A) and non structural 5A (NS5A) have direct
interactions with these two pathways. Core protein only in the monomeric form stimulates TLR2 pathway assisting
the virus to evade from the innate immune system. NS3/4A disrupts TLR3 and RIG-1 signaling pathways by cleaving
Toll/IL-1 receptor domain-containing adapter inducing IFN-beta (TRIF) and Cardif, the two important adapter
proteins of these signaling cascades respectively, thus halting the defense against HCV. NS5A downmodulates the
expressions of NKG2D on natural killer cells (NK cells) via TLR4 pathway and impairs the functional ability of these
cells. TLRs and RIG-1 pathways have a central role in innate immunity and despite their opposing natures to HCV
proteins, when exploited together, HCV as an ever developing virus against host immunity is able to accumulate
these mechanisms for near unbeatable survival.
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HCV infection is a major cause of acute hepatitis and
chronic liver disease. HCV was first identified in 1989
[1]. It is classified as a member of the Hepacivirus genus
within the family Flaviviridae. More than 200 million
people are living with HCV, which covers about 3.3% of
the world’s population [2]. It is also estimated that three
to four million people are infected with HCV each year
[3]. There are 6 genotypes of HCV, 52 subtypes within
these genotypes, as well as diverse population of quasis-
pecies within each infected individual. The source of this
variation, like that of other RNA viruses, is the high* Correspondence: mi.bannu786@yahoo.com
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reproduction in any medium, provided the ormutation rate of its error prone RNA polymerase [4].
The HCV genome is approximately 9.6 kb and encodes
an approximately 3000 amino acids long polyprotein.
Complicated quasispecies and frequent mutation of viral
genome have also emerged. The large HCV polyprotein
is cleaved by the host and viral proteases to generate at
least 10 proteins, including four structural proteins (core
protein, two envelope proteins, E1, E2, and p7 ion chan-
nel). The six non-structural proteins include NS2-NS3-
NS4A-NS4B-NS5A-NS5B-COOH [5]. These proteins
not only have a role in viral replication but also have an
important role in cellular function. Although there have
been several explanations suggested for HCV infection,
replication in targeted cells and escape from the immune
system, the actual mechanism is still not understood [6].
Patients in the advanced stages of chronic liver diseasetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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higher susceptibility to microbial infections and are con-
sidered to be immune compromised hosts [7]. Impaired
activation of TLR signaling may also have a role in the
susceptibility to infections in patients with liver cirrhosis
[8]. Innate immunity is made possible by a network of
germ-line encoded pattern-recognition receptors (PRRs),
which senses pathogen-associated molecular patterns
(PAMPs) on invading microbes and activate immuno-
logical responses. PRRs include the Nod-like receptors
(NLRs), RIG-like receptors (RLRs), Toll-like receptors
(TLRs) and the recently identify cytosolic DNA recep-
tors [9-12]. TLRs are evolutionarily conserved struc-
tures. They were initially demonstrated in the fruit fly
Drosophila melanogaster as an element governing its
body’s longitudinal growth as well as an anti-fungal
agent. Soon after that structures homologous to TLRs
were also characterized in higher animals, including
humans. They can recognize a variety of molecules that
are present in various pathogens and are essential for
their growth and survival. PAMPs are divided into sub-
families on the basis of their broad specificity, ranging
from TLR1 to TLR11 in human. TLRs are mainly
expressed on the cell surface (TLRs1, 2, 4, 5, 6, and 10).
However, some TLRs such as TLR3, 7, 8, and 9 are
located intracellularly [13]. Mechanisms responsible for
liver damage associated with chronic HCV infection re-
main incompletely understood, although increasing evi-
dence points to immunological rather than direct viral
effects [14-17]. Several bacterial infections such as sepsis
and cellulitis are more common in HCV-infected
patients than in those without HCV infection [7,18,19].
As TLR mediated proinflammatory cytokine responses
are necessary for host defense against bacteria [20], it is
likely that chronic HCV infection generates an immune
environment in which TLR-mediated proinflammatory
cytokine production is impaired after exposure to bac-
terial antigens. In this review article we focused on the
interaction of HCV proteins with TLRs & RIG1 and
how these interactions are exploited by HCV to escape
from the host innate immune system.
HCV core protein and TLRs
The HCV core protein possesses many functions. It
interacts with many cellular proteins and signal trans-
duction pathways of the host cell. Its main function is to
form the capsid shell that houses and protects the HCV
genomic RNA while the virus passes from one cell to
another or from one person to another [21]. When hu-
man embryonic kidney 293 cells (HEK293) and human
monocytic cell line, Mono Mac 6 (MM6) cell lines were
stimulated by HCV core protein; there was an induction
of IL-6 and IL-8 via TLR2 pathway. MyD88-deficient
splenocytes fail to produce IL-6 after stimulation withthe core protein further confirming the role of core pro-
tein in TLR2 signaling pathway as MyD88 is a down-
stream effector molecule of the TLR2 signaling cascade
[22]. Thus, core protein is a specific activator of the
TLR2-MyD88 signaling cascade, it causes the activation
of TLR2 on antigen-presenting cells (APCs) to induce
cytokines that are produced in response to nuclear
translocation of nuclear factor kappa B (NFκB) subunits
[21,22]. Although the ligation of TLRs on APCs induce
proinflammatory responses, pre-exposure to TLR2 or
TLR4 ligands desensitize APCs to subsequent stimula-
tion by TLRs [23-26]. Decreased production of TNFα in
response to challenge with a TLR ligand with which the
cells were pre-treated is defined as “homotolerance”,
while decreased activation to a TLR ligand that does not
share homology with the pretreatment ligand is called
“heterotolerance” [27]. TLR tolerance has a significant
role in protecting from hyperactivation of the immune
system and can be overcome by conditioning of innate
immune cells with cytokines, including interferons and
growth factors [27-29]. Exposure of MM6 cells to core
protein also induces homotolerance of TLR2 and cross
tolerance with TLR4 after subsequent stimulation with
TLR ligands. The induction of cross-tolerance by expos-
ure to core protein is impaired by blockage of the TLR2
pathway, because IL-6 production is significantly re-
duced in MM6 cells treated with an anti-TLR2 monoclo-
nal antibody [22].
The production of IL-6 and IL-8 by monocytes iso-
lated from HCV-infected patients are also significantly
decreased as compared to that of healthy control sub-
jects when cells are stimulated with core protein, pep-
tidoglycan Pam3CSK4, or lipopolysaccharide (LPS). The
continuous activation of TLR2 by core protein causes
decreased cytokine responses to TLR ligands in mono-
cytes from HCV-infected patients [30]. There is no con-
siderable correlation between serum levels of the core
antigen and TLR-induced IL-6 or IL-8 production. This
suggests that the serum concentration of the core anti-
gen is not responsible for hyporesponsiveness to TLR
ligands during chronic HCV infection. Other viral pro-
teins such as NS3/4A and host factors may also be
involved in the generation of hyporesponsiveness to TLR
ligands. Furthermore, there is no association between
patient age and the production of proinflammatory cyto-
kines in patients with chronic HCV infection [8].
Reduced production of IL-6 by peripheral blood mono-
nuclear cells (PBMCs) from chronic HCV patients is
associated with decreased platelet counts and prolonged
prothrombin time (PT). As these parameters are very
sensitive markers of liver function [7], it signifies that
liver dysfunction is associated with hyporesponsiveness
to TLR ligands in patients with chronic HCV infection.
Both viral and host factors have a role in the generation
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HCV infection. Platelet counts and PT can be used as
markers to determine TLR responses in patients with
chronic HCV infection [31]. Pre-activation with core
protein causes no significant alteration in the expression
of costimulatory molecules and TLRs, CD80, CD86,
TLR2, or TLR4 in MM6 cells. The expression of CD80
and CD86 is not changed by treatment with core protein
after re-stimulation with core protein or lipopolysacchar-
ide. It is improbable that the inhibition of TLR responses
by core protein pre-stimulation is due to the induction
of apoptotic cell death because the stimulation of MM6
cells with core protein has no effect on the percentage
of Annexin V + apoptotic cells [22].
Involvement of TLR2 corecptors
There is also a significant role for TLR2 coreceptors in
cellular activation by the core protein in human and
mouse cells. The absence of TLR1 or TLR6 had a strik-
ing negative effect on HCV core stimulation, suggesting
the role of both of these TLR2 coreceptors. Nonetheless,
selective silencing of only one coreceptor did not result
in the complete loss of cytokine induction by the HCV
ligands. The knockout mouse model demonstrates that
HCV core and NS3 use the TLR2/TLR6 complex. The
only minimal inhibition of HCV core induced TNF-α in
TLR1-/- recommends that in mice, recognition or acti-
vation of HCV core may not involve TLR1. As HCV
does not infect mice and their TLRs have slightly differ-
ent sequences than humans, it is not astonishing that
there may be some differences in the ligand activation
between these two TLR2 coreceptors. There is a signifi-
cant reduction in TNF-α in the HCV protein-stimulated
TLR6 knockout macrophages but the residual cytokine
production remained active. So, it means that there is
the possibility of an alternate use of TLR1 or the prob-
ability of the use of another TLR2 coreceptor, such as
CD36 (dectin-1) [32,33] or CD14 [34] in human beings.
Use of TLR1 or TLR6 as TLR2 coreceptors in macro-
phage activation by HCV core protein supports a poten-
tial for broad range identification and cell activation by
these proteins.
Evasion from the innate immune system
HCV core protein in monomeric form is sensed by
TLR2 as shown in Figure 1. On the contrary, neither re-
combinant nor serum derived infectious HCV results in
efficient activation of TLR2 signaling. Target cell lines
including human dendritic cells [35] and hepatocytes ex-
press TLR2 at noteworthy levels. It has been suggested
that HCV core sensed by TLR2 appears to be absent in
enveloped viral particles. Two mechanisms may explain
this evasion: (a) In intact viral particles, the core protein
may take conformation that might not be acknowledgedby TLR2; (b) the envelope glycoproteins in infectious
virions prejudice HCV core sensing by TLR2. It has been
shown that denaturation of monomeric core protein by
heat treatment completely abolishes TLR2 sensing, sup-
porting the first hypothesis of conformation dependent
sensing of core protein. The second hypothesis, impair-
ment of core sensing by the HCV envelope is supported
by the finding that the recombinant envelope glycopro-
teins and patient-derived HCV are not capable of stimu-
lating TLR2 signaling pathway [36]. HCV entry into host
cells is a complex process involving several binding and
entry factors that ultimately lead to decapsidation of the
virus inside the endosomal compartments and release of
viral RNA into the cytoplasm. As the monomeric core
protein, but not core as part of a nucleocapsid or sub-
viral particle interacts with TLR2, it is possible that HCV
particles are not sensed by cell surface expressed TLR2
during the steps of binding and entry. In vivo, TLR2
sensing and activation is most likely to be activated by
core protein that is resulted from degraded nucleocap-
sids or unassembled core protein which are released
from disintegrated infected hepatocytes at distinct sites
of the infected host. As recent studies have demon-
strated the evidence for intracellular expression of TLRs
[37], it is more feasible that core-TLR2 interaction and
activation may occur following viral uncoating or pro-
duction of monomeric protien in an intracellular com-
partment. Thus, only monomeric core protein but not
infectious viral particles is sensed by TLR2. Impairment
of core-TLR interaction in infectious particles may have
role to escape from innate antiviral immune responses
and facilitate persistence of HCV infection [36].
Evasion from the adaptive immune system
Defect in Th17 differentiation
Chronic exposure to the core protein leads to the devel-
opment of APCs with a limited ability to drive Th17 dif-
ferentiation. IL-17 (but not IFN-γ) production by
allogeneic naïve CD4+ T cells is clearly reduced when T
cells are cocultured with monocytes from HCV-infected
patients and with TLR ligands. This discriminating im-
pairment of the adaptive IL-17 response can be
explained by profiles of cytokine production by these
monocytes. IL-6 production induced by core protein and
TLR ligands is significantly decreased in monocytes from
HCV-infected patients as compared to healthy control
subjects; whereas IL-12p40 production is comparable in
monocytes from both populations. As IL-6 and IL-12
play an important role for Th17 and Th1 differentiation,
respectively [32,38,39], the defective IL-17 response in
allogeneic CD4+ T cells may be due to impaired IL-6
production by APCs from HCV-infected patients.
Chronic exposure to the core protein seems to impair
the adaptive IL-17 response (through the development
Figure 1 HCV monomeric core protein interacts with TLR2 and utilizes TLR1, TLR6 or some other receptor as a coerceptor.
Imran et al. Virology Journal 2012, 9:126 Page 4 of 10
http://www.virologyj.com/content/9/1/126of APCs with a limited ability to produce IL-6 after
stimulation with TLR ligands) without having any effect
on adaptive interferon gamma (IFN-γ) or transforming
growth factor beta (TGF-β) responses [40].
Defect in PDC modulation
HCV Core protein via TLR2 plays an important role in
the modulation of plasmacytoid cell (PDC) functions as
an anti-TLR2 antibodies (Abs) partially prevent the in-
hibitory effect of HCV core protein on TLR9-triggered
IFN-α production. Thus core protein exploits TLR2
pathway to reduce IFN-α production for its survival. IL-
10 [41] and TNF-α [42] are induced by TLR2 pathway.
Antibody neutralization of IL-10 and TNF-α repaired
IFN-α production in TLR9 plus HCV core stimulated
PBMCs. Additionally, rIL-10 and TNF-α repressed both
TLR9-induced IFN-α production and PDC apoptosis in
a dose dependent manner. It means that the microenvir-
onment, including the presence of cytokines and chemo-
kines, is fundamental for PDC function [43-46]. ILs 3, 4,
7, and 15 support IFN-α production of virus-infected
cells whereas TNF-α and IL-10 inhibit it [43]. Under
normal regulation TLR tolerance confines TNF-α pro-
duction and it is protected against excessive immune ac-
tivation and its harmful effects [47]. These protective
mechanisms are deregulated in HCV infected patients.
HCV patient’s monocytes fail to set homo and heteroto-
lerance to pro-inflammatory cytokine involving TLR
ligands, including TLR2/TLR1, TLR2/TLR6, TLR4, TLR3
and TLR7/8. HCV core protein [23,48] activates and
induces tolerance in normal but not in chronic HCV
monocytes and disturbs the regulation of cytokines.
NS3/4A and escape from the innate immune system
The role played by TLR3 in HCV infection is much
less convinced. NS3/4A is a non covalent enzymecomplex that possesses RNA helicase as well as prote-
ase activity. It leads to post-translational cleavage of
the polyprotein expressed by this positive-strand RNA
virus [49]. One of the most important host responses
to virus infection is the production of chemokines and
antiviral cytokines such as IFN-α and IFN-β. Virus-
induced IFN production is added by positive feedback
mechanisms via type I IFNs [50]. The initial step for
the stimulation of cytokine response in RNA virus in-
fection is cellular activation of dsRNA receptor sys-
tems, Toll-like receptor 3 (TLR3) [51,52] and retinoic
acid inducible gene-I (RIG-I) [53]. These two pathways
lead to the activation of IκB kinase (IKK) α/β/γ com-
plex and IKK-like kinases e.g. IKKE and TANK binding
kinase 1 (TBK1) [53-57]; which mediate the activation
and nuclear translocation of NFκB and interferon
regulatory factor 3 (IRF3) [58,59]. Inside the nucleus;
IRF3, NFκB and activator protein 1 (AP-1), transcrip-
tion factors stimulate type I IFN and proinflammatory
cytokine genes expression. Many viruses have evolved
the strategy to impede the effector mechanisms
induced through these pathways [60], but viral interfer-
ence with the significant proximal receptor interactions
has not yet been depicted. NS3/4A appears to mediate
proteolysis of a cellular protein within an antiviral sig-
naling pathway upstream of IRF-3. IFN-α (α1), IFN-β
and IFN-λ (λ1) genes are extremely sensitive to the in-
hibitory effect of NS3/4A. There is also an inhibitory
effect of NS3/4A on other cytokine/chemokine gene
promoters such as IFN-β, CCL5/RANTES,CXCL10/
IP-10, CXCL8/IL-8, TNF-α and IFN-α4. Thus, NS3/4A
protein is not only an effective antagonist of the IFN-β
promoter but also of other cytokine/chemokine pro-
moters. Inhibition of IRF-3 activation requires only
NS3/4A protease activity and is abrogated by a spe-
cific, peptido-mimetic protease inhibitor, SCH6 [61].
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TLR3 is expressed on endosomal membranes (and the
plasma membranes of some cells) and senses dsRNA
that is present in endosomal and/or extracellular com-
partments as shown in Figure 2 [62]. TLR3 signaling
pathway proceeds through the adaptor protein, TRIF
also called TICAM-1 [58]. TRIF is the only adaptor pro-
tein that is accessible for use by TLR3. It is due to the
presence of alanine in position 795 in the protruding
BB loop of the TIR domain rather than the conserved
proline common amongst other TLRs [58]. TRIF en-
compasses a TIR domain flanked by proline rich C and
N terminal domains. In resting cells, TRIF does not
co-localize with TLR3. It is found in diffused form
throughout the cellular cytosol. dsRNA binding to TLR3
transiently recruits TRIF to localize with TLR3 at the
membrane before its disassociation to form cytosolic
speckle structures [63]. TRIF contributes to amino acid
homology (Ser-Thr-Pro-Cys-Ser) with the HCV polypro-
tein NS4B/5A at the site of cleavage by NS3/4A [64,65].
Ectopically expressed TRIF is degraded in HEK293 and
osteosarcoma cells expressing HCV NS3/4A. Consist-
ent with this, polyinosinic:polycytidylic acid (poly I:C)-
induced activation of IRF-3 is blocked in HeLa cells
having HCV RNA replicons, and endogenous TRIF abun-
dance is reduced in these cells [65]. Poly I:C is a syn-
thetic dsRNA often used in studies investigating TLR3
function and signaling. However, others have not been
able to demonstrate cleavage of ectopically expressed
TRIF by NS3/4A [66].
Huh7 hepatoma cells, which are almost exceptional in
their ability to support HCV infection in vitro, are defi-
cient in TLR3 signaling due to a lack of TLR3 expression
[67]. The absence of an HCV permissive cell line having
functional TLR3/TRIF-dependent pathway has made it
difficult to determine that HCV infection is sensed by
TLR3. TLR3 is expressed in normal human hepatocytesFigure 2 HCV NS3/4A blocks two important adapter proteins, TRIF anin situ. Primary cultures of human hepatocytes have a
robust signaling pathway, it induces the expression of
interferon stimulated genes (ISGs) when stimulated by
poly I:C. TLR3 is also expressed by a transduced gene in
HCV permissive Huh7 cells. It senses HCV infection
and establishes cellular antiviral state that restricts HCV
replication. Compared to poly (I:C) stimulation, HCV in-
fection causes a delayed TLR3-dependent interferon
stimulating genes (ISG) response in hepatoma cells. This
suggests that HCV may not be recognized upon viral
entry. There is a requirement of HCV replication to gen-
erate an abundance of dsRNA that is sufficient to trigger
TLR3 signaling. TLR3-dependent nuclear translocation
of IRF-3 in HCV-infected cells suggests that dsRNA is
likely to be sensed within the cell in which it is produced.
The entrance of viral RNA into the endosomal com-
partment and its engagement by TLR3 within infected
cells is still uncertain. Conceivably, this could be accom-
plished through autophagy, as reported for TLR7 sensa-
tion of Vesicular stomatitis virus (VSV) infection in
PDC [68]. Rab5 is an early endosome protein which
colocalizes with the HCV RNA replication complex [69].
It is possible that TLR3 expression may also be localized
to intracellular membranes involved in HCV RNA repli-
cation [70]. This mechanism of immune evasion blocks
the expression of multiple host defense genes and con-
tributes to persistent infections. Moreover, the ability of
the protease active site to accommodate distinct sub-
strate interactions with TRIF represents a remarkable ex-
ample of RNA virus evolution. It may be the reason for
the unusual hallow active site conformation that distin-
guishes NS3/4A from other viral proteases [60]. The
cleavage of TRIF by NS3/4A characterizes a unique
broad mechanism of viral immune evasion.
RIG-I senses cytosolic dsRNA. The signaling cascade
involves an important adaptor protein, Cardif also called
as IPS-1/MAVS/VISA [59-61,71]. This protein is anotherd MAVS (Cardif) of the TLR3 signaling pathway.
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at Cys-508 residue, 32 amino acids from the C-terminus.
This results in the release of Cardif from the mitochon-
drial outer membrane and makes it incapable of func-
tioning in the RIG-I signaling pathway [71,72].
NS3 and TLR2
TLR2 mediated innate immune signaling pathways are
also stimulated by NS3 proteins. TLR2 activation
involves homo or hetero dimerization with TLR1 or
TLR6. NS3 stimulated TNFα and IL-10 production in
human monocyte derived macrophages is impaired by
TLR2, TLR1, and TLR6 knockdown. Contrary to human
data; results from TLR2, TLR1, or TLR6 knockdown
mice point out that the absence of TLR2 and its core-
ceptor TLR6, but not TLR1; prohibited NS3 protein
induced peritoneal macrophage activation. In conclu-
sion, TLR2 may use TLR1 and TLR6 coreceptors in
NS3-mediated activation of macrophages and innate im-
munity in humans [73].
NS3/4A and escape from the adaptive immune system
In addition to the impairment in virus-induced expres-
sion of type 1 IFNs, other cytokines induced by NS3/4A
could also suppress or delay successive adaptive CD8 T
cell responses. These responses are essential for HCV
elimination [74,75]. Interference of virus-activated NFκB
mediated responses can also promote viral persistence
[76]. The proteolytic processing of components of both
TLR3 and RIG-I pathways, lead to the abrogation of the
cascade that activates IRF3 and NFκB. This in turn fails
to induce genes that express IFN-α and -β, and add-
itional cytokines that are crucial for stimulating other
arms of the immune system.
Studies on PBMC and cell lines for NS5A and TLR4
interactions
HCV NS5A is a hydrophilic phosphoprotein playing an
important role in viral replication, modulation of cell
signaling pathways and interferon response [77,78]. Its
interaction with TLR4 has been suggested by various
reports [79-81]. PBMCs from HCV-infected individuals
show a higher expression level of TLR4 as compared to
healthy individuals. HCV infection causes increased
IFN-β and IL-6 secretion from B cells, particularly after
LPS stimulation. The increased IFN-β and IL-6 produc-
tion is attained by TLR4 induction because the introduc-
tion of small interfering RNAs against TLR4 specifcally
inhibits HCV-induced cytokine production. Taking into
account, all viral proteins, only NS5A causes TLR4 in-
duction in hepatocytes and B cells. NS5A specifcally sti-
mulates the promoter of the TLR4 gene in both
hepatocytes and B cells [79].On the other hand, TLR4 western blot analyses
showed significant down regulation of TLR4 expression
along with stable expression of HCV NS5A of genotype
1b in Huh-7 replicon cells. Huh-7 cells infected for 3
days with HCV genotype 2a (JFH1) also strongly
expressed reduced levels of TLR4 in comparison with
mock-infected cells. This suggests that NS5A downregu-
lates TLR4 expression in hepatocytes. The molecular
mechanisms by which NS5A decreased TLR4 expression
in hepatocytes suggested that NS5A reduced TLR4 ex-
pression, at least in part, by hampering TLR4 transcrip-
tion in hepatocytes. This reduction of TLR4 expression
is not by its destabilization through direct interaction
with NS5A. NS5A down regulates the expression of
molecules involved in the formation of the TLR4 recep-
tor complex such as MD-2, CD14. It also reduces the
expression of downstream signaling molecules, MyD88,
NFκB, and IRF3 [80]. Various genotypes of NS5A bind
to MyD88 which is a major adaptor molecule in TLRs as
shown in Figure 3. This binding hampered the recruit-
ment of interleukin-1 receptor-associated kinase 1 to
MyD88, and impaired cytokine production in response
to TLR ligands. Amino acid residues 240 to 280 previ-
ously recognized as the interferon sensitivity-determining
region (ISDR) in NS5A interact with the death domain of
MyD88. The expression of a mutant NS5A lacking the
ISDR to some extent restored cytokine production [81].
NS5A and escape from the immune system
HCV NS5A activates TLR4 pathway [82]. NS5A potently
increases the production of anti-inflammatory cytokines
IL-10 and TGFβ via the TLR4 pathway. Blocking IL-10 or
its receptor abrogated the NS5A-induced TGFβ secretion
in a dose-dependent manner. Thus NS5A-stimulated
TGFβ production is related to autocrine IL-10 release.
TLR4 activation may have a role in IL-10 producing via
p38 and PI3K [83]. TLR4 signaling leads to the down-
stream stimulation of NFkB, MAPK (p38 and JNK) and
PI3K pathways [20]. PI3K is an endogenous suppressor of
IL-12 production triggered by TLR4 [84]. Altogether,
NS5A interacts with TLR4 on monocytes and leads to the
secretion of IL-10 through p38 and PI3 kinase pathways
and concurrently suppresses the production of proinflam-
matory IL-12. The NKG2D are activating receptors that
are present on NK cells. NKG2D usually detects the pres-
ence of infectious non-self and/or stress-induced self
ligands on the surface of infected cells. They are constitu-
tively expressed on human NK and CD8 T cells [85]. Its
ligands are approximately undetectable in normal tissues,
but are stimulated on the cell surface by various stresses
such as DNA damage, tumor transformation and intracel-
lular infection. The importance of the NKG2D defense
system is highlighted by the observation that tumors and
viruses have developed several strategies for evading
Figure 3 HCV NS5A blocks Myd88 of the TLR4 pathway.
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tion of the NKG2D pathway in the control of HCV infec-
tion is unclear [87,88]. IL-10 triggered secretion of TGFβ
leads to down modulation of NKG2D expression, which
in turn leads to impaired effector functions of NK cells.
The functional consequences of this NKG2D reduction
are associated with impaired production of IFNγ and
CD107a degranulation by NK cells [82].Conclusion
The interaction of HCV proteins with TLRs & RIG-1 is a
complex process as shown in Table 1. It stimulates various
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